• Paeoniflorin and Tmem176b+ Macrophages in Liver I/R

  2026-09-02

  This 2025 study uses single-cell RNA sequencing and macrophage-depletion experiments to identify Tmem176b+ macrophages as an important cellular target of paeoniflorin in hepatic ischemia-reperfusion injury. Its findings connect macrophage-state remodeling with THBS1-CD47 and SPP1-CD44 signaling, offering a mechanistic framework for studying immune regulation during liver injury.

• Bestatin (Ubenimex): An Assay-First Guide

  2026-09-02

  Bestatin, also called Ubenimex, is a selective aminopeptidase inhibitor with applications in enzyme profiling, cancer research, and multidrug resistance studies. This assay-first guide explains how to interpret its potency, design orthogonal readouts, and distinguish aminopeptidase perturbation from RIPK3-dependent necroptosis biology.

• Cleavage-Resistant TREM2 Reprograms Efferocytosis

  2026-09-02

  Dong et al. engineered a synthetic cleavage-resistant TREM2 receptor that preserves DAP12 signaling and restores macrophage efferocytosis during inflammation. Phosphatidylserine-functionalized lipid nanoparticles delivered CRT mRNA in situ, reducing apoptotic-cell accumulation and inflammatory pathology in mouse models of MASH and atherosclerosis.

• Cy5 RNA Labeling Kit for Mechanistic Assays

  2026-09-01

  The HyperScribe T7 High Yield Cy5 RNA Labeling Kit supports adjustable fluorescent RNA probe synthesis for hybridization-based assays. This article explains how Cy5-UTP incorporation can be used as a measurement-design variable, including its careful application to mechanistic studies inspired by ROS-responsive mRNA delivery research.

• Isoproterenol in Human Pacemaker Modeling

  2026-08-31

  Human SAN-plexus assembloids create a powerful setting for separating intrinsic pacemaker maturation from acute beta-adrenergic stimulation. This article outlines how Isoproterenol sulfate dihydrate can serve as a translational challenge tool for connecting GPCR signaling, cAMP/PKA biology, electrophysiology, and neuro-cardiac disease modeling.

• IPA-3 Workflows for Selective Pak1 Signaling

  2026-08-31

  IPA-3 enables mechanistic Pak1 pathway studies without the interpretive complications of ATP-site competition. This guide translates its biochemical and cell-based use into practical assay workflows, while showing why a negative antiviral result can be as informative as pathway inhibition.

• 11β-HSD1 Inhibition Reprograms Liver Fibrosis

  2026-08-30

  A 2025 mouse study shows that inhibiting 11β-HSD1 reduces thioacetamide-induced liver fibrosis through coordinated suppression of Notch signaling and enhancement of natural killer cell responses. The work connects local cortisol metabolism with hepatic stellate-cell activation and immune-mediated clearance, providing a mechanistic framework for future liver fibrosis research.

• IRG1–Itaconic Acid Control of TBK1 Signaling

  2026-08-29

  Chai et al. identify an IRG1–itaconic acid feedback pathway that restrains TBK1-driven type I interferon production by alkylating TBK1 at Cys605 and disrupting its dimerization. The study also introduces ITA-5 and ITA-9 as itaconic acid-based candidate inhibitors, providing a mechanistic link between infection-associated metabolism and control of hyperinflammation.

• Nonselective β-Blockers and HCT Engraftment

  2026-08-28

  The reference study shows that nonselective β-adrenergic blockade can impair hematopoietic regeneration after allogeneic hematopoietic cell transplantation, whereas β1-selective blockade has a substantially different effect. Mouse experiments and human cohort analyses connect this finding to β2/β3-adrenergic signaling, transplant type, posttransplant therapy, and hematopoietic cell dose.

• Propidium Iodide Workflows for Cell Analysis

  2026-08-28

  Propidium iodide converts plasma-membrane damage into a measurable red-fluorescence signal for viability, apoptosis, necrosis, and DNA-content workflows. This guide connects practical PI assay design with a lactoferrin-processing study, showing how controlled sample handling can improve interpretation without overextending the evidence.

• PART1–miR-503-5p–FOXK1 in Ovarian Cancer

  2026-08-28

  Li et al. identified a regulatory axis in which lncRNA PART1 promotes ovarian cancer phenotypes by suppressing miR-503-5p and sustaining FOXK1 expression. The study combines expression analysis, functional assays, target validation, rescue experiments, and a xenograft model to connect this pathway with tumor-cell viability, migration, invasion, and apoptosis.

• E-64 in Protease Mechanism and Epithelial Signaling

  2026-08-27

  E-64 is an irreversible L-trans-epoxysuccinyl peptide that enables precise cysteine protease inhibition. This article connects its assay utility with cytokine- and glucocorticoid-regulated epithelial signaling, translating BIRC2/BIRC3 biology into practical experimental decisions.

• Bafilomycin C1 in High-Content Cardiotoxicity Assays

  2026-08-26

  Bafilomycin C1 adds a controlled lysosomal-pH perturbation to high-content iPSC-cardiomyocyte workflows, helping distinguish morphology, viability, autophagy, and trafficking phenotypes. This practical guide combines V-ATPase biology with deep-learning image analysis, dose optimization, and troubleshooting for more interpretable screening data.

• Meropenem Trihydrate for Resistance Phenotyping

  2026-08-26

  Meropenem trihydrate provides a mechanistic carbapenem antibiotic anchor for studying cell-wall inhibition and resistant Enterobacterales. This article explains how to combine phenotypic testing with LC-MS/MS metabolomics for more informative antibiotic resistance studies.

• LAMP1, CXCL10-CXCR3, and Macrophage Polarization

  2026-08-26

  The 2024 International Immunopharmacology study identifies LAMP1-dependent autophagy as a state-sensitive switch linking the CXCL10-CXCR3 axis to macrophage polarization. Its cell and mouse experiments show that CXCL10 can promote either M2- or M1-like responses depending on inflammatory context, while CXCR3 antagonism reduced poly(I:C)-associated lung injury.

555 records 6/37 page Previous Next First page 上5页 678910 下5页 Last page